Reviewing Microbot Medical (NASDAQ:MBOT) and Sonova (OTCMKTS:SONVY)
by Renee Jackson · The Cerbat GemMicrobot Medical (NASDAQ:MBOT – Get Free Report) and Sonova (OTCMKTS:SONVY – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.
Risk & Volatility
Microbot Medical has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Sonova has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.
Earnings and Valuation
This table compares Microbot Medical and Sonova”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Microbot Medical | N/A | N/A | -$11.44 million | ($0.45) | -5.36 |
| Sonova | $4.36 billion | 3.43 | $610.01 million | N/A | N/A |
Sonova has higher revenue and earnings than Microbot Medical.
Analyst Ratings
This is a summary of current recommendations and price targets for Microbot Medical and Sonova, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Microbot Medical | 1 | 1 | 2 | 0 | 2.25 |
| Sonova | 3 | 4 | 1 | 1 | 2.00 |
Microbot Medical currently has a consensus price target of $8.75, indicating a potential upside of 263.07%. Given Microbot Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Microbot Medical is more favorable than Sonova.
Institutional and Insider Ownership
16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 0.0% of Sonova shares are owned by institutional investors. 4.7% of Microbot Medical shares are owned by company insiders. Comparatively, 0.0% of Sonova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Microbot Medical and Sonova’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Microbot Medical | N/A | -37.06% | -34.44% |
| Sonova | N/A | N/A | N/A |
Summary
Sonova beats Microbot Medical on 6 of the 11 factors compared between the two stocks.
About Microbot Medical
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
About Sonova
Sonova Holding AG manufactures and sells hearing care solutions for adults and children in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It operates through two segments, Hearing Instruments and Cochlear Implants segments. The Hearing Instruments segments engages in the design, development, manufacture, distribution, and service of hearing instruments and related products, as well as wireless headsets, speech-enhanced hearables, and audiophile headphones under the Phonak, Unitron, Hansaton, and Sennheiser brand names; and audiological care services under the AudioNova, Audium, Audition Santé, Boots Hearingcare, Connect Hearing, Geers, Hansaton, Lapperre, Schoonenberg, and Triton Hearing brands. The Cochlear Implants segment is involved in the design, development, manufacture, distribution, and service of hearing implants and related products under the Advanced Bionics brand. The company sells its products through independent distributors; and provides hearing care services through a network of stores and clinics. The company was formerly known as Phonak Holding AG and changed its name to Sonova Holding AG in August 2007. Sonova Holding AG was founded in 1947 and is headquartered in Stäfa, Switzerland.